EP4013468A1 - Matière cellulaire pour greffe osseuse dérivée de la moelle osseuse - Google Patents

Matière cellulaire pour greffe osseuse dérivée de la moelle osseuse

Info

Publication number
EP4013468A1
EP4013468A1 EP20760786.2A EP20760786A EP4013468A1 EP 4013468 A1 EP4013468 A1 EP 4013468A1 EP 20760786 A EP20760786 A EP 20760786A EP 4013468 A1 EP4013468 A1 EP 4013468A1
Authority
EP
European Patent Office
Prior art keywords
bone
bone graft
scaffold
cells
graft material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20760786.2A
Other languages
German (de)
English (en)
Inventor
Dirk Henrich
Ingo MARZI
Peter Bader
Selim KUÇI
Zyrafete KUÇI
Thomas KLINGEBIEL
Halvard Bönig
Erhard Seifried
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Goethe Universitaet Frankfurt am Main
Original Assignee
Goethe Universitaet Frankfurt am Main
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goethe Universitaet Frankfurt am Main filed Critical Goethe Universitaet Frankfurt am Main
Publication of EP4013468A1 publication Critical patent/EP4013468A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/12—Phosphorus-containing materials, e.g. apatite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants

Definitions

  • the invention pertains to the use of bone marrow derived cells (BMDC) except mesenchymal stem cells (MSC) in the treatment of bone disorders or injuries.
  • BMDC bone marrow derived cells
  • MSC mesenchymal stem cells
  • the invention provides BMDC and preparations of specifically pooled BMDC for use in the manufacturing of bone graft material for implanting into or attaching to bones in order to enhance bone regeneration after surgery or injury, or to treat various bone disorders, such as osteonecrosis.
  • the invention provides bone graft material, a method for its production, bone graft implants, and medical methods and uses of the inventive products.
  • Bone formation and degradation are tightly regulated by growth factor signalling between osteoblasts that are responsible for bone formation and osteoclasts that are responsible for bone re-absorption.
  • Coupling bone formation by osteoblasts with degradation by osteoclasts has recently become a topic of intense study; with the list of growth factors identified as coupling factors expanding.
  • Coupling bone formation with bone re-absorption requires the recruitment of osteoblasts and osteoclasts in parallel with the recruitment of their respective progenitor cells.
  • Osteoblasts derive from mesenchymal stem cell (MSC) while osteoclasts derive from monocytes that are a part of the myeloid-lineage; however, it remains unknown how MSC or monocytes migrate from their niche in the bone marrow to sites of new bone formation.
  • MSC mesenchymal stem cell
  • monocytes also migrate from their bone marrow niche to the endosteal surface; where they subsequently differentiate into osteoclasts that re-absorb bone.
  • Growth factors known to regulate bone formation include TGF -, BMP- and the canonical Wnt-ligands.
  • Osteoclast formation from monocyte precursors and bone re absorption are regulated through the expression of MSCF, OPG and RANK-ligand.
  • osteoclast activity is also regulated by the expression of the TGF -, BMP- and the non-canonical Wnt-ligands.
  • TGF -, BMP- and the Wnt-ligands promote bone formation and re-absorption. The maintenance of healthy bone requires constant remodelling, in which bone is made and destroyed continuously.
  • MSCs are stromal cells that are plastic-adherent and able to differentiate into osteoblasts, chondroblasts, and adipocytes. They express biomarkers including CD73, CD90, and CD105, and they must not express CD14 or CDub, CD34.
  • MSC can be derived mainly from bone marrow, but also umbilical cord blood or from other sources. In particular bone marrow derived MSC have been most extensively studied both in preclinical and clinical experiments: the effects of such MSC in fracture healing, spinal fusion, and osteonecrosis have been demonstrated (Su P, et al, Int J Mol Sci. 2018 Aug 9;i9(8)).
  • the invention pertains to bone graft material for use in the treatment of a subject, comprising a scaffold material and a biological cell material, wherein the biological cell material comprises cell material genetically allogenic to the subject; wherein the bone graft material and the biological cell material does not comprise MSCs.
  • the invention pertains to bone graft implant, comprising a scaffold material and a biological cell material, wherein the bone graft implant is in the form of an implantable tablet having a height of l to 10 mm, preferably 3 to 5 mm, and/or a diameter of 1 to 15 mm, preferably 5 to 8 mm; wherein the bone graft implant does not comprise MSCs.
  • the invention pertains to a method for producing cryopreserved bone graft material, and wherein the bone graft material does not comprise MSCs comprising the steps of
  • the invention pertains to a method of producing a bone graft implant, the method comprising the step of compressing a bone graft material recited in any one of the preceding claims into a tablet, preferably having a height of 1 to 10 mm, preferably 3 to 5 mm, and/or a diameter of 1 to 15 mm, preferably 5 to 8 mm; and wherein the bone graft material does not comprise MSCs.
  • the invention pertains to a therapeutic kit, the kit not comprising MSCs, but comprising
  • a first container comprising a scaffold material recited in any one of the preceding aspects
  • a second container comprising a biological cell material recited in any one of the preceding aspects.
  • the invention pertains to a bone marrow derived cell (BMDC), or a BMDC preparation for use in the treatment of a disease, wherein the treatment comprises the administration of the BMDC, or the BMDC preparation, to a subject in need of the treatment by adhering the BMDC or BMDC preparation to a bone graft material to obtain an BMDC -bone graft material, and implanting or attaching the BMDC -bone graft material into/to one or more bone(s) of the patient; and wherein the BMDC do not comprise MSC.
  • BMDC bone marrow derived cell
  • the invention pertains to a use of a BMDC, or a BMDC preparation, in the manufacture of a medicament, preferably a bone graft material, for use in the treatment of a bone injuiy or disorder.
  • the invention pertains to bone graft material, comprising a scaffold material and a biological cell material, wherein the biological cell material comprises cell material genetically allogenic to the subject to be treated with the bone graft material; and wherein the bone graft material does not comprise MSC.
  • the bone graft material of the invention is for use in the treatment of a subject.
  • BMDCs bone marrow derived cells
  • CD117+ cells including hematopoietic stem cells, endothelial progenitor cells and other progenitor cells, and does not include or comprise mesenchymal stem (or stromal) cells (MSC).
  • MSC mesenchymal stem
  • EPCs endothelial progenitor cells
  • cell material as used in context of the present invention shall in particular pertain to materials comprising biological cell material, such as living or dead cells, preferably living cells, as well as any secreted factors derived from the culturing of such cells. In certain preferred embodiments, however, the present invention pertains to cell material comprising living biological cells.
  • biological cell in context of the invention shall preferably refer to a mammalian cell, most preferably a human cell. Certain embodiments of the invention pertain to cell compositions that do not comprise mesenchymal stromal cells.
  • the term "mesenchymal stromal cell” is a multipotent stromal cell that can differentiate into a variety of cell types, including, but not limited to osteoblasts (bone cells), chondrocytes (cartilage cells), myocytes (muscle cells) and adipocytes (fat cells). These cells are also known as “mesenchymal stem cells” due to their multipotency. This biologically important cell population is able to support haematopoiesis, can differentiate along mesenchymal and non-mesenchymal lineages in vitro, is capable of suppressing alloresponses and appears to be non -immunogenic.
  • Preferred cells used as cell material according to the invention are hematopoietic stem cells or EPCs, or similar progenitor cells derived from bone marrow.
  • the MSC according to the invention is in some preferred embodiments provided as a monogenic composition, therefore, such composition comprises cells of only one genetic background (or derived from one single donor subject).
  • Other embodiments, which might be preferred in context of the invention then pertain to a cell preparation that comprises BMDC derived from multiple genetically distinct donor subjects.
  • Preferred BMDC preparations are those which are prepared correspondingly as MSCs according to the methods described in PCT/EP2015/066083 (published as WO 2016/008895; disclosed herein by reference in its entirety, and specifically the method for generating MSC preparations comprising a step of pooling MSC from more than one genetically distinct donor before MSC isolation from such cell pool).
  • BMDC bone marrow mononuclear cell
  • the cell material is allogenic to the subject treated with the bone graft material of the invention.
  • allogenic or allogeneic refers to cells, tissues or organs that are not genetically identical or are derived from a non-genetically identical source to the transplant recipient (e.g., a non-related donor), especially with respect to antigens or immunological reactions.
  • Such cells, tissues or organs are called allografts, allogeneic transplants, homografts or allotransplants.
  • the invention in addition pertains to bone graft material that comprises scaffold material that is suitable for implantation into or attachment onto a mammalian bone.
  • scaffold material is intended to refer to a composition that is capable of forming a scaffold, i.e. a pre-scaffold material.
  • the scaffold material may comprise a composition that is capable of setting into a scaffold.
  • the scaffold material itself may or may not have a structure of a scaffold until the scaffold material has formed the scaffold according to the methods herein.
  • Reference to "a composition that is capable of forming a scaffold” may include the capability to form a scaffold with no further intervention/process steps or components.
  • reference to "a composition that is capable of forming a scaffold” may include the capability to form a scaffold following further intervention/process steps according to the invention herein and/or following addition of components according to the invention herein.
  • the term “scaffold” (may be interchanged with the term “matrix”) is understood to mean a solid mass of material having a 3 -dimensional structure, which may for example be suitable to support cells.
  • the scaffold maybe porous, having interconnected pores or gaps.
  • the scaffold material is synthetic or natural, preferably wherein the scaffold material comprises calcium phosphate, preferably a-, or b- tricalciumphosphate (TCP), or comprises polylactic acid or polycarpolactone (or other biodegradable polymer), or a mixture of these materials.
  • Natural scaffold material is for example obtained from bones or dental material.
  • Naturally-derived bone scaffold materials are usually prepared by acid extraction of most of the mineralized component to result in so called demineralized bone matrix (DBM).
  • DBM demineralized bone matrix
  • Examples for naturally-derived materials are Bio-Oss® of the mineral portion of bovine bone or Algipore® a porous calcium phosphate material of algae.
  • Autologous (or allogentic) bone is an ideal source of graft material, not only due to its biocompatibility, but also because natural bone grafts facilitate reossification of the defect site by promoting or conducting ingrowth of the patient's own bone tissue to the defect site. Methods for obtaining such material are well known to the person of skill in the art.
  • An additional preferred source of natural bone scaffold material is the use of heat-inactivated spongiosa which is prepared by removing cartilage from a femoral head and heating it to more than 6o°C, preferably to more than 8o°C, preferably about 90°C, for more than to minutes (preferably about an hour).
  • the aforementioned b-TCP is one crystal form of a composition represented by Ca 3 (P0 4 ) 2 , which is a biocompatible compound that is stable at normal temperature.
  • b- TCP commercially available b-TCP powders and b-TCP blocks, for example, b-TCP blocks to be used as scaffold material may be used, or the b-TCP can be produced by a publicly known method (Japanese unexamined Patent Application Publication No. 2004-26648, etc.) or from an a-TCP powder (Japanese unexamined Patent Application Publication No. 2006-89311, etc.).
  • the b-TCP composition of the present invention may be a b-TCP composition substantially composed of b-TCP or a b-TCP composition produced by mixing in a surfactant, water and so on
  • the b-TCP composition may be a b-TCP powder obtained by processing a b- TCP block into particles or granules
  • the b-TCP composition is preferably a polycrystalline, high-strength and high-density b-TCP dense body having a low porous rate obtained by densificating a b-TCP powder by tablet pressing or after defoaming by sintering, and among such b-TCP dense bodies, one having a porous rate of 50% or more is preferable.
  • a b-TCP dense body refers to b-TCP having a porous rate of 50% or more. Also in the present invention, powders, particles, and granules all indicate the granular form, and there is no substantial distinction among them. Pores in the b-TCP dense body are determined according to the size and number of spaces between the particles of the polycrystal.
  • the porous rate of b-TCP can be measured by using a micro CT (Bertoldi S, Fare S, Tanzi MC. Assessment of scaffold porosity: the new route of micro-CT. J Appl Biomater Biomech. 2011 Sep-Dec;9(3):i65-75- doi: 10.5301/JABB.2011.8863. Review) a mercury intrusion method, in which pressure is applied to force mercury into a pore and the specific surface area and pore distribution are obtained from the pressure applied and the amount of mercury intruded, or from the density using a calibration curve.
  • the porous rate P can also be measured using, for example, the ACCUPYC 1330 series (the product of Shimadzu Corporation).
  • the porous rate in the b-TCP block as measured by the mercury intrusion method is preferably 50 to 90%, more preferably 60 to 85%, and even more preferably 70 to 80%.
  • a b-TCP powder having a particle diameter of 75 to 105 pm can be produced by pulverizing a b-TCP block, and the porous rate of each powder thus produced as measured by the mercury intrusion method is preferably 50 to 90%, more preferably 55 to 85%, and even more preferably 57 to 80%, and a preferable average porous rate is 60 to 70%.
  • a b-TCP microgranule having a particle diameter of 25 pm or less can also be produced by pulverizing a b-TCP block into particles.
  • the porous rate of the b-TCP microgranule thus produced as measured by the mercury intrusion method is preferably 50% or more, more preferably 50% to 90%.
  • the b-TCP dense body can include a b-TCP powder, particle, granule, tablet, and columnar body having a porous rate of 50% or more.
  • These b-TCP dense bodies may consist exclusively of b-TCP or comprise b-TCP as scaffold for the MSC seeded on the material as active ingredient, as well as other components.
  • densifi cation of a b-TCP powder by sintering is performed by sintering preferably at above 600 °C to 2000 °C, more preferably at 750 to 1500 °C, and even more preferably at 900 to 1300 °C, and preferably for 1 to too hours, more preferably for 10 to 80 hours, and even more preferably for 20 to 50 hours.
  • sintering can be divided into multiple operations and performed at a plurality of different temperatures.
  • a rod shaped b-TCP dense body can also be produced by the following method.
  • a slurry is prepared by mixing calcium hydrogen phosphate, calcium carbonate, and water at an appropriate ratio, and the slurry thus prepared is allowed to undergo reaction while grinding, followed by drying. Subsequently, the solid material obtained after drying is pulverized and calcined to give a b-TCP powder.
  • the b-TCP powder thus obtained is formed into a columnar body by compression forming. The resulting compression-formed columnar body is sintered at 600 °C to 1300 °C for about 20 hours.
  • the scaffold material is a nanoporous material.
  • nanoporous generally refers to a porous material (i.e. a calcium phosphate ceramic) whose average pore diameter is in the nanometer range (typically between 1 to 1000 nm). More preferably, the pores of the nanoporous material of the invention are communicating nanopores, which preferably are pores which are interconnected via channels. Such communicating pores preferably have a degree of porosity and interconnection that there is a channel connection from one side of the graft to the other.
  • a porosity according to the invention is preferably a porosity of 50% - 90%, preferably of 60% - 70%; and/ or wherein the nanopores have an average diameter of 50 - 600 pm, preferably of too - 500 pm; and/ or wherein the nanopores are communicating nanopores.
  • the scaffold material is preferably not a decellularized tissue matrix obtained from natural, such a xenogeneic (non-human) tissues.
  • the term “decellularized” or “decellularization” as used herein refers to a biostructure (e.g., a tissue or an organ, or part of an organ), from which the cellular content has been removed leaving behind an intact acellular infra-structure mainly composed of collagens.
  • the bone graft material is in the form of an implantable tablet, preferably a tablet having cylindrical shape (rod-shaped).
  • cylindrical shape refers to any geometrical shape having the same cross section area throughout the length of the geometrical shape.
  • the cross section of a cylinder within the meaning of the present invention may have any two dimensional shape, for example the cross section may be circular, oval, rectangular, triangular, angular or star shaped.
  • the pharmaceutical compositions described herein have a cylindrical shape, wherein the end(s) are optionally tapered.
  • a bone graft material according to the invention is a tablet having a height of 1 to 10 mm, preferably 3 to 5 mm, and/or a diameter of 1 to 15 mm, preferably 5 to 8 mm.
  • the tablet of the invention with the herein disclosed dimensions showed surprisingly improved effects for the performance of the MSC during the treatment.
  • the “length” refers to the dimension of the longest axis of the tablet and the “height” refers to the dimension of the longest axis in the largest plane of the tablet. The diameter therefore refers to the axis perpendicular to the height.
  • the bone graft material of the invention is cryopreserved, and thus optionally requires thawing immediately before surgical insertion or attachment to the bone of a patient.
  • cryopreservation refers to the process of cooling and storing biological cells, tissues, or organs at low temperatures to maintain their viability.
  • cryopreservation can be the technology of cooling and storing cells at a temperature below the freezing point (e.g., -20 °C or colder, -80 °C or colder, or the like) that permits high rates of survivability of the cells upon thawing.
  • the biological material seeded onto the scaffold material is ideally cryopreserved in order to provide an off-the-shelf product for implantation.
  • the invention pertains to bone graft implant, comprising a scaffold material and a biological cell material, wherein the bone graft implant is in the form of an implantable tablet having a height of 1 to 10 mm, preferably 3 to 5 mm, and/or a diameter of 1 to 15 mm, preferably 5 to 8 mm; the bone graft material not comprising MSC.
  • the bone graft implants may be made from allograft, autograft, xenograft, cortical, cancellous, cartilage, and combinations of, synthetic HA, B-TCP, Ceramic, PLA, PLGA, PLLA or other such materials and may be incorporated with growth factors, plasma (e.g., platelet rich plasma), platelets (e.g., intact platelets), cells, peptides or other such materials.
  • growth factors e.g., platelet rich plasma
  • platelets e.g., intact platelets
  • cells peptides or other such materials.
  • the bone graft implants are cylinders, rectangular, trapezoidal, flat, convex, concave, and may have a channel on one or both sides for easy placement against a patient's bone or for buttressing against a bone.
  • the bone graft implants may be trimmed to size and snapped onto a rod by press fit or by means of sutures.
  • the bone graft implant biological cell material comprises living cells, preferably allogenic or autologous. More preferably the biological cell material is the biological cell material as described herein for the first aspect of the invention.
  • the bone graft material, cellular composition or other compounds, materials and composition described herein in the various aspects of the invention preferably do not comprise added, and preferably immobilized, bone growth factors or cytokines.
  • Such growth factors and cytokines are often added in order to render cells in bone graft material osteo-inductive.
  • the materials of the present invention in all aspects and embodiments thereof preferably do not require such addition of osteo-inductive cytokines or growth factors since the cellular compositions of the invention are inherently osteo-inductive.
  • Such cytokines include bone morphogenic protein (BMP), Indian hedgehog (IHH), transforming growth factor b (TGF3); bone morphogenetic proteins (BMPs); fibroblast growth factors (FGFs); Wnt ligands and b-catenin; insulin-growth factors (IGFs); collagen-i; Runx2; osteopontin; osterix; vascular endothelial growth factor (VEGF); platelet derived growth factor (PDGF); osteoprotegerin (OPG); NEL-like protein 1 (NELL-i ); or a mixture thereof.
  • BMP bone morphogenic protein
  • IHH Indian hedgehog
  • TGF3 transforming growth factor b
  • BMPs bone morphogenetic proteins
  • FGFs fibroblast growth factors
  • IGFs insulin-growth factors
  • collagen-i Runx2
  • osteopontin osterix
  • VEGF vascular endothelial growth factor
  • PDGF platelet derived growth factor
  • the bone graft implant according to the invention is preferably cryopreserved.
  • the invention pertains to a method for producing or manufacturing a cryopreserved bone graft material; the bone graft material not comprising MSCs, comprising the steps of
  • cryopreservation medium is used in order to minimize the loss of cell material during the process.
  • cryopreservation medium or "ciyoprotectant” is a substance that is used to protect eukaryotic cells (and also tissues, organs) from freezing damage. Further, the cryopreservation agent or ciyoprotectant may protect the eukaryotic cells (and also tissues or organs) from cold and heat shock, dehydration, and cryo-toxicity during cryopreservation. The cryopreservation agent or cryoprotectant may be cell penetrating or non-penetrating.
  • cryoprotectants include glycerol, DMSO (dimethyl sulfoxide), propylene glycol, ethylene glycol, acetamide, and methanol.
  • DMSO dimethyl sulfoxide
  • cryoprotectants have some disadvantages in that they can induce protein denaturation at higher temperature and cause cryoprotectant toxicity in cellular systems (like tissues and organs).
  • the toxicity of the cryoprotectants is a major limitation to successful cryopreservation of eukaryotic cells.
  • DSMO is a preferred cryoprotectant for use in accordance with the present invention.
  • the cryopreservation is performed at -15 °C or less, preferably is -20 °C or less, preferably less than -50 °C (about -70 °C or -80 °C); preferably the cryopreservation comprises a step of freezing at a freezing temperature of less than -20 °C, such as -40 °C or less, and subsequent storing of at temperatures higher than the freezing temperature.
  • the scaffold material for us in the process of the invention is in granulate form, preferably wherein the granules have an average size of 0.1 to 3 mm, preferably 0.5 to 3 mm, more preferably 0.7 to 2.8 mm, more preferably 1.4 to 2.8 mm.
  • the scaffold material is already provided in the form of an implantable body, such as a tablet or rod, preferably in cylindrical shape.
  • the biological cell material is seeded on the scaffold material in accordance with some embodiments of the invention in a density of at least 0.1 x to 6 cells per mL scaffold material, preferably of at least 0.5 x 10 6 cells per mL scaffold material, more preferably of about 1 x 10 6 cells per mL scaffold material.
  • the invention pertains to a method of producing a bone graft implant, the method comprising the step of compressing a bone graft material recited in any one of the preceding claims into a tablet, preferably having a height of 1 to 10 mm, preferably 3 to 5 mm, and/or a diameter of 1 to 15 mm, preferably 5 to 8 mm; wherein the bone graft implant does not comprise MSCs.
  • the invention pertains to a therapeutic kit, the kit not comprising MSCs; comprising
  • a first container comprising a scaffold material recited in any one of the preceding aspects
  • the present invention further provides a therapeutic kit comprising separate containers of the biological cell material and the scaffold material.
  • a therapeutic kit comprising separate containers of the biological cell material and the scaffold material.
  • it is intended to mix the cell material directly with the scaffold material before medical use. For example, either the biological cell material is immediately combined with the scaffold material before surgical implantation, or alternatively, before the combination the biological cell material is expanded by in-vitro culturing to provide higher cell numbers before application.
  • the first and the second container may have any form suitable for packaging their respective materials.
  • the container are formed such to allow a direct mixing of the content of the first container with the content of the second container to obtain the final product for use in the treatment. Syringes are one example of such containers.
  • the therapeutic kit of the invention may comprise additional components useful for realizing a medical treatment of the invention. Buffers, media, or instructions for use are non limiting examples of such additional components.
  • the invention pertains to a bone marrow derived cell (BMDC), or a BMDC preparation for use in the treatment of a disease, wherein the treatment comprises the administration of the BMDC, or the BMDC preparation, to a subject in need of the treatment by adhering the BMDC or BMDC preparation to a bone graft material to obtain an BMDC -bone graft material, and implanting or attaching the BMDC -bone graft material into/to one or more bone(s) of the patient; wherein the BMDC do not comprise MSC.
  • BMDC bone marrow derived cell
  • the invention pertains to a use of a BMDC, or a BMDC preparation, in the manufacture of a medicament, preferably a bone graft material, for use in the treatment of a bone injury or disorder.
  • a bone injury or disorder preferably selected from aseptic bone necrosis (spontaneous or therapy induced), bone fractures, fractures with secondary dislocation, pseudo- arthrosis, and reduced and delayed bone build-up.
  • Bone disorder treatable by the invention are any condition affecting the development and/or the structure of the skeletal system.
  • Bone disorders can include any disorder that results in an imbalance in the ratio of bone formation to bone resorption such that, if unmodified, a subject will exhibit less bone than desirable, or a subject's bones will be less intact and coherent than desired.
  • Bone disorders may refer to disorders, diseases, conditions or traumas of bone, such as fractures, osteoporosis, osteoarthritis, or cancers.
  • a bone disorder may result from fracture, from surgical intervention or from dental or periodontal disease. These diseases have a variety of causes and symptoms known in the art. Bone disorders can affect people of all ages, from newborns to older adults. However, certain age groups are more likely to have certain types of disorders.
  • the uses and methods according to the above aspects may in certain preferred embodiments comprise a step of culturing the BMDC, or BMDC preparation and in particular the BMDC comprised in the graft material of the invention, before implantation.
  • the uses and methods of the invention comprise a step of culturing for at least 6h, preferably at least i2h, more preferably at least i8h, more preferably at least 24h, even more preferably at least 36h and most preferably at least 48h or more.
  • the indicated culture times are commenced immediately after thawing the frozen BMDC preparation and before implantation. Maximum culture times are up to 96h, or less, for example 7h - most preferred is a culturing time of 24 to 72h, or for about 48I1.
  • a method for thawing a bone graft material according to the invention and preparing the bone graft material for implantation comprising a step of culturing the BMDC comprised in the bone graft material for at least 6h, preferably at least i2h, more preferably at least i8h, more preferably at least 24h, even more preferably at least 36I1 and most preferably at least 48I1 or more.
  • the indicated culture times are commenced immediately after thawing the frozen BMSC preparation and before implantation. Maximum culture times are up to 96I1, or less, for example 7I1 - most preferred is a culturing time of 24 to 72h, or for about 48I1.
  • the term “comprising” is to be construed as encompassing both “including” and “consisting of’, both meanings being specifically intended, and hence individually disclosed embodiments in accordance with the present invention.
  • “and/or” is to be taken as specific disclosure of each of the two specified features or components with or without the other.
  • a and/or B is to be taken as specific disclosure of each of (i) A, (ii) B and (iii) A and B, just as if each is set out individually herein.
  • the terms “about” and “approximately” denote an interval of accuracy that the person skilled in the art will understand to still ensure the technical effect of the feature in question.
  • the term typically indicates deviation from the indicated numerical value by ⁇ 20%, ⁇ 15%, ⁇ 10%, and for example ⁇ 5%.
  • the specific such deviation for a numerical value for a given technical effect will depend on the nature of the technical effect.
  • a natural or biological technical effect may generally have a larger such deviation than one for a man-made or engineering technical effect.
  • the specific such deviation for a numerical value for a given technical effect will depend on the nature of the technical effect.
  • a natural or biological technical effect may generally have a larger such deviation than one for a man-made or engineering technical effect.
  • Item 1 A bone graft material for use in the treatment of a subject, comprising a scaffold material and a biological cell material, wherein the biological cell material comprises cell material genetically allogenic to the subject, and wherein the biological cell material does not comprise MSC.
  • Item 2 The bone graft material for use according to item 1, wherein the biological cell material comprises living cells.
  • Item 3 The bone graft material for use according to item 1 or 2, wherein the biological cell material, and preferably the graft material is cryopreserved.
  • Item 4 The bone graft material for use according to any one of items 1 to 3, wherein the biological cell material comprises cells derived from any source, or comprises bone marrow mononuclear cells (BMC).
  • BMC bone marrow mononuclear cells
  • Item 5 The bone graft material for use according to any one of items 1 to 4, wherein the biological cell material comprises living cells of one donor subject, preferably of more than two genetically distinct donor subjects, preferably from at least 3, 4, 5, 6, 7, 8. 9 or 10 or more genetically distinct donor subjects.
  • Item 6 The bone graft material for use according to item 5, wherein the biological cell material is obtained from, or derived from, a pooled preparation of bone marrow samples, or bone marrow mononuclear cell fractions, of the genetically distinct donors, in accordance with a method as described in WO 2016/008895.
  • Item 7 The bone graft material for use according to any one of items 1 to 6, wherein the treatment comprises surgical insertion or attachment of the bone replacement material to a bone of the subject.
  • Item 8 The bone graft material for use according to any one of items 1 to 7, wherein the treatment is for promoting bone growth or healing, such as for example to treat a bone injury or disorder selected from bone fracture, bone trauma, arthrodesis, a bone deficit condition associated with post-traumatic bone surgery, post-prosthetic joint surgery, post-plastic bone surgery, post-dental surgery, bone chemotherapy treatment, congenital bone loss, post traumatic bone loss, post-surgical bone loss, post infectious bone loss, allograft incorporation or bone radiotherapy treatment, and preferably in the treatment of osteonecrosis (avascular necrosis (AVN)).
  • avascular necrosis Avascular necrosis
  • Item 9 The bone graft material for use according to item 8, wherein the osteonecrosis is a secondary disease caused by corticosteroid treatment, trauma, alcohol, sickle cell disease, leukaemia or other known causes of osteonecrosis, or is idiopathic osteonecrosis.
  • Item 10 The bone graft material for use according to any one of items 1 to 9, wherein the biological cell material is adsorbed on the scaffold material.
  • Item 11 The bone graft material for use according to any one of items 1 to 10, wherein the scaffold material is synthetic or natural, preferably wherein the scaffold material comprises calcium phosphate, preferably a-, or b-tricalciumphosphate (TCP), or comprises polylactic acid or polycaprolactone (or other biodegradable polymer), or a mixture of these materials.
  • the scaffold material is synthetic or natural, preferably wherein the scaffold material comprises calcium phosphate, preferably a-, or b-tricalciumphosphate (TCP), or comprises polylactic acid or polycaprolactone (or other biodegradable polymer), or a mixture of these materials.
  • Item 12 The bone graft material for use according to any one of items 1 to 11, wherein the scaffold material is a nanoporous material with a porosity of 50% - 90%, preferably of 60% - 70%; and/or wherein the nanopores have an average diameter of 50 - 600 pm, preferably of 100 - 500 pm; and/or wherein the nanopores are communicating nanopores.
  • the scaffold material is a nanoporous material with a porosity of 50% - 90%, preferably of 60% - 70%; and/or wherein the nanopores have an average diameter of 50 - 600 pm, preferably of 100 - 500 pm; and/or wherein the nanopores are communicating nanopores.
  • Item 13 The bone graft material for use according to any one of items 1 to 12, which is in the form of an implantable tablet, preferably a tablet having cylindrical shape.
  • Item 14 The bone graft material for use according to item 13, wherein the tablet has a height of 1 to 10 mm, preferably 3 to 5 mm, and/ or a diameter of 1 to 15 mm, preferably 5 to 8 mm.
  • Item 15 The bone graft material for use according to any one of items 1 to 14, which is cryopreserved and requires thawing immediately before surgical insertion or attachment.
  • Item 16 A bone graft implant, comprising a scaffold material and a biological cell material, wherein the bone graft implant is in the form of an implantable tablet having a height of l to 10 mm, preferably 3 to 5 mm, and/or a diameter of 1 to 15 mm, preferably 5 to 8 mm.
  • Item 17 The bone graft implant according to item 16, wherein the biological cell material comprises living cells, preferably allogenic or autologous.
  • Item 18 The bone graft implant according to item 16 or 17, which is cryopreserved.
  • Item 19 The bone graft implant according to any one of items 16 to 18, wherein the biological cell material comprises cells derived from any source, or comprises bone marrow mononuclear cells (BMC).
  • Item 20 The bone graft implant according to any one of items 16 to 19, wherein the biological cell material comprises living cells of more than two genetically distinct donor subjects, preferably from at least 3, 4, 5, 6, 7, 8. 9 or 10 or more genetically distinct donor subjects.
  • Item 21 The bone graft implant according to any one of items 16 to 20, wherein the scaffold material is the scaffold material recited in any one of items 1 to 15.
  • Item 22 The bone graft implant according to any one of items 16 to 21, for a use recited in any one of items 1 to 15.
  • Item 23 A method for producing cryopreserved bone graft material, comprising the steps of (i) Seeding biological cell material as recited in any one of items 1 to 22 on a scaffold material as recited in any one of items 1 to 22 to obtain a bone graft material, and
  • Item 24 The method according to item 23, wherein the bone graft material is cryopreserved in a cryopreservation medium, for example a DSMO containing cryopreservation medium.
  • a cryopreservation medium for example a DSMO containing cryopreservation medium.
  • Item 25 The method according to item 23 or 24, wherein cryopreservation is at less than -15 °C or less, preferably is -20 °C or less, preferably less than -50 °C (about -70 °C or -80 °C); preferably the cryopreservation comprises a step of freezing at a freezing temperature of less than -20 °C, such as -40 °C or less, and subsequent storing of at temperatures higher than the freezing temperature.
  • Item 26 The method according to any one of items 23 to 25, wherein the scaffold material is in granulate form, preferably wherein the granules have an average size of 0.1 to 3 mm, preferably 0.5 to 3 mm, more preferably 0.7 to 2.8 mm, more preferably 1.4 to 2.8 mm.
  • Item 27 The method according to any one of items 23 to 26, wherein the biological cell material is seeded on the scaffold material in a density of at least 0.1 x 10 6 cells per mL scaffold material, preferably of at least 0.5 x 10 6 cells per mL scaffold material, more preferably of about 1 x to 6 cells per mL scaffold material.
  • Item 28 A method of producing a bone graft implant, the method comprising the step of compressing a bone graft material recited in any one of the preceding items into a tablet, preferably having a height of 1 to 10 mm, preferably 3 to 5 mm, and/ or a diameter of 1 to 15 mm, preferably 5 to 8 mm; the bone graft material not comprising MSC.
  • Item 29 A therapeutic kit, comprising
  • a first container comprising a scaffold material recited in any one of the preceding items
  • a second container comprising a biological cell material recited in any one of the preceding items; wherein the (i) and (ii) are provided in the therapeutic kit in separate containers for combining immediately before surgical insertion; and wherein the kit does not comprise MSC.
  • Item 30 The therapeutic kit according to item 29, further comprising two syringes suitable for combining the biological cell material with the scaffold material.
  • Item 31 The therapeutic kit according to item 29 or 30, for use in medicine, preferably for use in the treatment of a bone disease or injury, and preferably of osteonecrosis.
  • Item 32 A BMDC, or a BMDC preparation, for use in the treatment of a disease, wherein the treatment comprises the administration of the BMDC, or the BMDC preparation, to a subject in need of the treatment by adhering the BMDC or BMDC preparation to a bone graft material to obtain an BMDC -bone graft material, and implanting or attaching the BMDC - bone graft material into/to one or more bone(s) of the patient.
  • Item 33 A use of a BMDC, or a BMDC preparation, in the manufacture of a medicament, preferably a bone graft material, for use in the treatment of a bone injury or disorder.
  • Figure 1 shows the metabolic activity of cells seeded on b-TCP, frozen and thawed
  • FIG. 2 shows a photograph of the tablet of the invention
  • MSC were applied at a density of 1x106 cells per cm 3 b-TCP according to established seeding protocols and cultivated for 3h at 37°C and then first frozen at -8o°C (overnight) and then -196°C (7 days) (experimental group). Metabolic activity was determined by MTT test in parallel cultures 24h and 48h after thawing. The control group consisted of MSC seeded at the same density and in the same manner on b-TCP, but incubated for 24h at 37°C only. Subsequently, the metabolic activity was also determined.
  • Comparative Example 1 Collection of bone marrow from 8 healthy third-party donors and isolation of BM-MNCs.
  • MSCs expressed the typical markers for MSCs, such as CD73, CD90 and CD105 but were negative for hematopoietic cell markers e.g. CD14, CD34, CD45. According to trypan blue staining the viability of these MSCs before freezing was 95 ⁇ 5%.
  • the total number of MSCs was distributed in 210 cryovials each containing 1.5x1o 6 MSC Pi and finally frozen in the gaseous phase of liquid nitrogen until use.
  • the inventors referred to this set of vials as MSC-bank.
  • the MSC as isolated according to comparative example 2 have improved alio suppressive potential as can be derived from WO 2016/008895.
  • the scaffold should consist of natural or synthetic matrices e.g. a-TCP, b-TCP, demineralized bone matrix, polylactic acid or polycaprolactone.
  • the scaffold should preferably be mechanically stable in order to prevent collapsing during surgical procedures and implantation.
  • the scaffold should offer communicating macropores of the size range too pm to 500 pm. Pore sizes from too pm improve angiogenesis, while pore diameters of 300-400 pm have a positive effect on osteoconductivity. Micropores enabling surface enlargement, cellular adhesion and improvement of nutritional support should range fromi pm to 10 pm. Overall porosity of the scaffold should be 60 - 70%, thus ensuring highest possible degree of porosity without compromising the mechanical strength.
  • the surface of the material should be rather smooth, rough microstructures in size range 1 - 10 pm should be prevented.
  • the surface consists of smooth slightly convex structures with a diameter ranging from 8-15 pm that are arranged in a honey comb similar matter.
  • Example 2 Manufacture of a bone implant graft
  • MSC derived from the cell bank of comparative example 2 were seeded to the scaffolds as described in Henrich et al, 2009, 2013, 2014; Seebach et al 2010, 2012, 2015. In brief, cells were harvested and preferably adjusted to a density of i*io 6 cells/mL (Range 1 - i*io 7 cells/mL). The cell suspension is carefully dripped on an equal volume of scaffold.
  • Cryopreservation will be performed preferably immediately after the seeding procedure but time span between seeding and cryopreservation may vary in a cell type dependent manner from o min to 24hrs. In the latter case the scaffold will be stored in medium (DMEM + 5% platelet lysate) at 37 °C, 5% CO2, 100% humidity until cryopreservation procedure takes place.
  • medium DMEM + 5% platelet lysate
  • cryopreservation medium preferably consisting of physiologic NaCl solution (65 % v/v, final NaCl concentration 0.7%), human serum albumin solution (HSA, 25% v/v, final HSA concentration 5%) and DMSO (10% v/v).
  • the cryopreservation medium is provided in sterile plastic bags. After addition of cell seeded scaffolds (range 1 to 20 scaffolds per bag), the bags are closed by heat sealing. The sealed bags were immediately subjected to a controlled rate freezer. Long term storage will be performed in liquid nitrogen vapor phase. The possibility for short term storage at -30 °C to -20 °C will be analysed. While the example shows the use of MSC, the inventive BMDC preparations work in a similar fashion.
  • Example 4 Thawing and use of bone graft implants
  • MSC were seeded on approximately 200 pL densely compressed b-TCP granules (size 1.4 -2.8 mm) in a density of i*io 6 cells/mL b-TCP- scaffold.
  • the seeding procedure consists of repeated dripping of the cell suspension over the scaffolds during a period of 30 minutes. Subsequently scaffolds were immediately frozen at -80 °C overnight in a medium containing 10% DMSO and 90% FCS.
  • As control, MSC on b-TCP (same donor) were cultivated at 37 °C in parallel. All procedures described in the following were also performed with the control approach.
  • Metabolic cell equivalent (MCE) of frozen and thawed MSC was 2.7M0 4 and around 25% of MSC cultured at 37 °C on b-TCP (5.8*104 MCE). If MSC were cultured additional 24hrs after thawing, the metabolic activity remained approximately constant (2.6*IO 4 MCE) compared to cell activity directly measured after thawing (2.7M0 4 MCE) whereas the metabolic activity of MSC cultured permanently at 37 °C increased further (1.7M0 5 MCE) compared to the initial value (i.2*io 5 MCE, Figure 1). These results indicate that MSC seeded on a B-TCP scaffold can be stored frozen at -80 °C and remain in part vital. Furthermore, it can be concluded that frozen/thawed MSC did not further deteriorate 24hrs after thawing, though they did not improve either. One might assume that the freeze/thaw procedure induced a lag phase of MSC proliferation.
  • MSC-Pool 8 donors, passage 2 was obtained from the Clinic for Pediatrics and Adolescent Medicine. The cells were further cultivated up to a maximum of the 5th passage and used in experiments, or cryopreserved for later experiments. MSC phenotype was activated by FACS analysis (CD90+, CD105+, CD34-, CD45-) and the ability for osteogenic differentiation.
  • the metabolic activity of the cells was measured on the day after sowing for the control group and 1 and 2 days after rethawing using the MTT test.

Abstract

L'invention concerne l'utilisation de cellules dérivées de la moelle osseuse, à l'exception des cellules souches mésenchymateuses, dans le traitement de troubles ou de lésions osseuses. L'invention concerne des cellules dérivées de la moelle osseuse et des préparations de cellules dérivées de la moelle osseuse spécifiquement regroupées pour utilisation dans la fabrication d'une matière pour greffe osseuse destinée à être implantée dans des os ou à être fixée à ceux-ci afin d'améliorer la régénération osseuse après une intervention chirurgicale ou une lésion, ou pour traiter divers troubles osseux, tels que l'ostéonécrose. L'invention concerne une matière pour greffe osseuse, son procédé de production, des implants pour greffe osseuse, et des procédés médicaux et des utilisations des produits de l'invention.
EP20760786.2A 2019-08-16 2020-08-17 Matière cellulaire pour greffe osseuse dérivée de la moelle osseuse Pending EP4013468A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19192114 2019-08-16
PCT/EP2020/073000 WO2021032681A1 (fr) 2019-08-16 2020-08-17 Matière cellulaire pour greffe osseuse dérivée de la moelle osseuse

Publications (1)

Publication Number Publication Date
EP4013468A1 true EP4013468A1 (fr) 2022-06-22

Family

ID=67659108

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20760786.2A Pending EP4013468A1 (fr) 2019-08-16 2020-08-17 Matière cellulaire pour greffe osseuse dérivée de la moelle osseuse

Country Status (2)

Country Link
EP (1) EP4013468A1 (fr)
WO (1) WO2021032681A1 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2432583A1 (fr) 2002-06-20 2003-12-20 Merck Patent Gesellschaft Mit Beschraenkter Haftung Methode de preparation de poudres de phosphates tricalciques alpha et beta
JP2006089311A (ja) 2004-09-22 2006-04-06 Toyo Kohan Co Ltd β−リン酸三カルシウム多孔体、その製造方法及び生体材料
US20080033572A1 (en) * 2006-08-03 2008-02-07 Ebi L.P. Bone graft composites and methods of treating bone defects
EP2274023B1 (fr) * 2008-04-10 2019-12-11 Bonus Therapeutics Ltd Implants prothétiques de type osseux
EP2975118B1 (fr) 2014-07-16 2016-08-24 Johann Wolfgang Goethe-Universität, Frankfurt am Main Génération d'une banque de cellules stromales mésenchymateuses provenant des cellules mononucléaires en pool de donneurs de moelle osseuse multiples
EP3435920A4 (fr) * 2016-04-01 2019-12-04 New York Stem Cell Foundation, Inc. Greffons d'implants osseux hybrides sur mesure

Also Published As

Publication number Publication date
WO2021032681A1 (fr) 2021-02-25

Similar Documents

Publication Publication Date Title
Stanovici et al. Bone regeneration strategies with bone marrow stromal cells in orthopaedic surgery
US20200237955A1 (en) Bioactive Grafts and Composites
JP5154729B2 (ja) 多孔質人工骨移植片およびその製造方法
Parikh Bone graft substitutes in modern orthopedics
AU2010328427B2 (en) Bioactive grafts and composites
US6277151B1 (en) Cartilage growth from cell seeded ceramic compositions
JP5759370B2 (ja) 組織工学および骨の再生のための、構造化された多孔率を有するモネタイトの三次元マトリクス、および、当該三次元マトリクスの調製方法
JP5792633B2 (ja) モネタイトと他の生物活性カルシウムの複合物及びシリコン化合物に基づく骨再生材料
US20230084724A1 (en) Method for producing hydroxyapatite-bioglass materials, said materials and products thereof
EP3031479A1 (fr) Compositions pour la reconstruction osseuse
US9421227B2 (en) Biomaterials containing calcium phosphate
US20220305058A1 (en) Mesenchymal stromal cell bone graft material
Daculsi et al. The micro macroporous biphasic calcium phosphate concept for bone reconstruction and tissue engineering
BR112012014263B1 (pt) Implante ortopédico osteocondutivo de memória de formato poroso e implante ortopédico maleável
EP4013468A1 (fr) Matière cellulaire pour greffe osseuse dérivée de la moelle osseuse
Daculsi et al. 20 years of biphasic calcium phosphate bioceramics development and applications
Goel et al. Role of tricalcium phosphate implant in bridging the large osteoperiosteal gaps in rabbits
US20190151501A1 (en) Bioactive grafts and composites
Heymann et al. Bone substitutes: new concepts
US20240024534A1 (en) Bioactive grafts and composites
Maheshwari et al. Bicalcium Phosphate as an Asset in Regenerative Therapy
AU2014218483B2 (en) Bioactive grafts and composites
RU2269961C2 (ru) Способ аутотрансплантации иммобилизованных стромальных стволовых клеток костного мозга
Biomate’riaux THE IVIICRO IVIACROPOROUS BIPHASIC CALCIUIVI PHOSPHATE CONCEPT FOR BONE RECONSTRUCTION AND TISSUE ENGINEERING
Danti et al. Bone tissue engineering: natural origination or synthetic polymeric scaffolds?

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220315

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230918